Suppr超能文献

杂合性 HTRA1 无义或移码突变是致病的。

Heterozygous HTRA1 nonsense or frameshift mutations are pathogenic.

机构信息

AP-HP, Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis, France.

Université de Paris, INSERM UMR-1141 Neurodiderot, Paris F-75019, France.

出版信息

Brain. 2021 Oct 22;144(9):2616-2624. doi: 10.1093/brain/awab271.

Abstract

Heterozygous missense HTRA1 mutations have been associated with an autosomal dominant cerebral small vessel disease (CSVD) whereas the pathogenicity of heterozygous HTRA1 stop codon variants is unclear. We performed a targeted high throughput sequencing of all known CSVD genes, including HTRA1, in 3853 unrelated consecutive CSVD patients referred for molecular diagnosis. The frequency of heterozygous HTRA1 mutations leading to a premature stop codon in this patient cohort was compared with their frequency in large control databases. An analysis of HTRA1 mRNA was performed in several stop codon carrier patients. Clinical and neuroimaging features were characterized in all probands. Twenty unrelated patients carrying a heterozygous HTRA1 variant leading to a premature stop codon were identified. A highly significant difference was observed when comparing our patient cohort with control databases: gnomAD v3.1.1 [P = 3.12 × 10-17, odds ratio (OR) = 21.9], TOPMed freeze 5 (P = 7.6 × 10-18, OR = 27.1) and 1000 Genomes (P = 1.5 × 10-5). Messenger RNA analysis performed in eight patients showed a degradation of the mutated allele strongly suggesting a haploinsufficiency. Clinical and neuroimaging features are similar to those previously reported in heterozygous missense mutation carriers, except for penetrance, which seems lower. Altogether, our findings strongly suggest that heterozygous HTRA1 stop codons are pathogenic through a haploinsufficiency mechanism. Future work will help to estimate their penetrance, an important information for genetic counselling.

摘要

杂合错义 HTRA1 突变与常染色体显性脑小血管病 (CSVD) 相关,而杂合 HTRA1 终止密码子变异的致病性尚不清楚。我们对 3853 名连续就诊的 CSVD 患者进行了所有已知 CSVD 基因(包括 HTRA1)的靶向高通量测序,这些患者均进行了分子诊断。在该患者队列中,杂合 HTRA1 突变导致提前出现终止密码子的频率与大型对照数据库中的频率进行了比较。对多个携带终止密码子的 HTRA1 载体患者进行了 HTRA1 mRNA 分析。对所有先证者进行了临床和神经影像学特征分析。在 20 名携带杂合 HTRA1 变异导致提前出现终止密码子的无亲缘关系的患者中发现了该变异。与对照数据库相比,观察到了非常显著的差异:gnomAD v3.1.1 [P=3.12×10-17,优势比 (OR)=21.9]、TOPMed freeze 5 (P=7.6×10-18,OR=27.1) 和 1000 Genomes (P=1.5×10-5)。对 8 名患者进行的信使 RNA 分析显示,突变等位基因降解强烈提示单倍不足。临床和神经影像学特征与之前报道的杂合错义突变携带者相似,除了外显率较低。总的来说,我们的研究结果强烈表明,杂合 HTRA1 终止密码子通过单倍不足机制导致致病性。未来的工作将有助于估计其外显率,这是遗传咨询的重要信息。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验